Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027
Industry Outlook
Alpha thalassemia treatment market accounted for a market value of US$ 526.1 Mn in 2018 and projected to grow at a CAGR of 7.1% during the forecast period from 2019 to 2027. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.
"Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period"
In 2018, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.
"Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period"
The Asia Pacific will grow gradually throughout the forecast period from 2018 to 2026, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.
Historical & Forecast Period
The alpha thalassemia treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
This report provides detailed research study related to alpha thalassemia treatment market covering market interpretations and assumptions included based on brief qualitative and quantitative data research carried out through primary and secondary research. Industry experts have value-added and assisted to analyze market dynamics such as drivers, opportunities & challenges further segmented to region-level & country-level. This report also comprises comprehensive analysis of global alpha thalassemia treatment market segmented as types of drug, and geography. The report also gives data related to competitive landscape of the major companies present and operate in alpha thalassemia treatment market that covers detailed information including company information such as latest business strategies, financial data, & product profiles.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2017-2027 |
| Base Year | 2018 |
| Forecast Period | 2019-2027 |
| Historical Year | 2017 |
| Unit | USD Million |
| Segmentation |
Type of Drug (2017–2027; US$ Mn) |
|
Pipeline Analysis |
|
|
Geography Segment (2017–2027; US$ Mn) |
The key companies present in the market analyzed & presented based on product portfolio, current market updates, financial information, and key strategies. This report also covers attractive investment proposition evaluated with the help of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co., and Gilead Sciences, Inc. among others.
Key questions answered in this report
- Which is the trending drug type in the market preferred for alpha thalassemia treatment & Why?
- What are the current market strategies & policies planned & applied by key companies & competitive landscape of the alpha thalassemia treatment market?
- Which are the important & potential geographical markets (regions and countries) in alpha thalassemia treatment market?
- Which is the largest and fastest growing region globally?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global ATT Market Portraiture
2.2. Global ATT Market, by Type of Drug, 2018 (US$ Mn)
2.3. Global ATT Market, by Geography, 2018 Vs 2027 (Value %)
Chapter 3. Global Alpha Thalassemia Treatment (ATT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018
Chapter 4. Global Alpha Thalassemia Treatment (ATT) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Folic Acid
4.3. Deferasirox
4.4. Deferiprone
4.5. Hydroxyurea
Chapter 5. Global Alpha Thalassemia Treatment (ATT) Market, Pipeline Analysis
5.1. Overview
5.2. Darbepoetin Alfa (Phase III)
5.3. Enriched Hematopoetic Stem Cell Infusion (Phase II)
5.4. In utero hematopoietic stem cell transplantation (Phase I)
Chapter 6. Global Alpha Thalassemia Treatment (ATT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America ATT Market Analysis, 2017 – 2027
6.2.1. North America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.2.2. North America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe ATT Market Analysis, 2017 – 2027
6.3.1. Europe ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.3.2. Europe ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific ATT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America ATT Market Analysis, 2017 – 2027
6.5.1. Latin America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.5.2. Latin America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.6.2. MEA ATT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. GlaxoSmithKline Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bellicum Pharmaceuticals
7.3. Novartis AG
7.4. Acceleron Pharma
7.5. Johnson & Johnson
7.6. Merck & Co Inc.
7.7. Alnylam Pharmaceuticals Inc.
7.8. Calimmune Inc.
7.9. Editas Medicine Inc.
7.10. Gilead Sciences Inc.
* Here we are using ATT as a short form of Alpha Thalassemia Treatment
TABLE 1 Global Alpha Thalassemia Treatment (ATT) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 2 North America ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 3 North America ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 5 Europe ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa ATT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Bellicum Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Acceleron Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Merck & Co Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Alnylam Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Calimmune Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Editas Medicine Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Gilead Sciences Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Alpha Thalassemia Treatment (ATT): Market Segmentation
FIG. 2 Global ATT Market Share, by Type of Drugs, 2018 (US$ Mn)
FIG. 3 Global ATT Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Folic Acid Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Deferasirox Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Deferiprone Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Hydroxyurea Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Darbepoetin Alfa Market for ATT, Till 2027 (US$ Mn)
FIG. 11 U.S. ATT Market, 2017 – 2027 (US$ Mn)
FIG. 12 Canada ATT Market, 2017 – 2027 (US$ Mn)
FIG. 13 U.K. ATT Market, 2017 – 2027 (US$ Mn)
FIG. 14 Germany ATT Market, 2017 – 2027 (US$ Mn)
FIG. 15 Rest Of Europe ATT Market, 2017 – 2027 (US$ Mn)
FIG. 16 Japan ATT Market, 2017 – 2027 (US$ Mn)
FIG. 17 China ATT Market, 2017 – 2027 (US$ Mn)
FIG. 18 Rest Of Asia Pacific ATT Market, 2017 – 2027 (US$ Mn)
FIG. 19 Brazil ATT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Mexico ATT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest Of Latin America ATT Market, 2017 – 2027 (US$ Mn)
FIG. 22 GCC ATT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest Of Middle East And Africa ATT Market, 2017 – 2027 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)